| NASDAQ (usa) |   | 6715.56 | -12.11 | -0.18% | 
| FTSE 100 (london) |  | 7487.96 | -5.12 | -0.07% | 
| DAX (german) |   | 13465.51 | 235.94 | 1.78% | 
| NIKKEI 225 (japan) |   | 22420.08 | 408.47 | 1.86% | 
| Hang - Seng (hong kong) |   | 28594.06 | 348.52 | 1.23% | 
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |   | 3391.61 | 17.53 | 0.52% | 
| KOSPI (korea) |   | 2556.47 | 33.04 | 1.31% | 
| All Ordinaries (australia) |   | 6005.30 | 28.90 | 0.48% | 
| BOVESPA (brazil) |   | 74092.76 | -215.73 | -0.29% | 
Zymeworks Inc (NYSE: ZYME)
                                    	ZYME Technical Analysis
                                    
                                    
    5
    
    
    
    
									| As on 30th Oct 2025 ZYME WS- Price closed @ 19.12 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 12.15 & Strong Buy for SHORT-TERM with Stoploss of 9.22 we also expect STOCK to react on Following IMPORTANT LEVELS. | 
ZYMEWS- Price
| Open | 19.28 | Change | Price | % | 
| High | 19.98 | 1 Day | -0.26 | -1.34 | 
| Low | 18.86 | 1 Week | 1.19 | 6.64 | 
| Close | 19.12 | 1 Month | 2.63 | 15.95 | 
| Volume | 848124 | 1 Year | 9.97 | 108.96 | 
| 52 Week High 19.30 | 52 Week Low 8.36 | ||||
    NYSE USA Most Active Stocks
                    | FSR | 0.02 | 0.00% | 
| DDR | 15.44 | -4.46% | 
| PFE | 24.29 | 0.00% | 
| TWTR | 53.70 | 0.66% | 
| ABEV | 2.30 | 5.50% | 
| SWN | 7.11 | -0.56% | 
| CMG | 32.53 | -18.18% | 
| BACA-U | 302.00 | 0.67% | 
| ENLC | 14.12 | -0.21% | 
| NOK | 7.13 | -2.73% | 
NYSE USA Top Gainers Stocks
                    
                NYSE USA Top Losers Stocks
                    
                | ZYME Daily Charts | ZYME Intraday Charts | Whats New @ Bazaartrend | ZYME Free Analysis | 
|  | 
ZYME Important Levels Intraday
                                    | RESISTANCE | 21.28 | 
| RESISTANCE | 20.59 | 
| RESISTANCE | 20.16 | 
| RESISTANCE | 19.73 | 
| SUPPORT | 18.51 | 
| SUPPORT | 18.08 | 
| SUPPORT | 17.65 | 
| SUPPORT | 16.96 | 
ZYME Forecast  October 2025
                                    | 4th UP Forecast | 24.69 | 
| 3rd UP Forecast | 22.9 | 
| 2nd UP Forecast | 21.8 | 
| 1st UP Forecast | 20.7 | 
| 1st DOWN Forecast | 17.54 | 
| 2nd DOWN Forecast | 16.44 | 
| 3rd DOWN Forecast | 15.34 | 
| 4th DOWN Forecast | 13.55 | 
     ZYME Weekly Forecast
                                    
                                    
                                | 4th UP Forecast | 20.93 | 
| 3rd UP Forecast | 20.35 | 
| 2nd UP Forecast | 19.99 | 
| 1st UP Forecast | 19.63 | 
| 1st DOWN Forecast | 18.61 | 
| 2nd DOWN Forecast | 18.25 | 
| 3rd DOWN Forecast | 17.89 | 
| 4th DOWN Forecast | 17.31 | 
ZYME Forecast2025
                                    | 4th UP Forecast | 41.8 | 
| 3rd UP Forecast | 34.53 | 
| 2nd UP Forecast | 30.03 | 
| 1st UP Forecast | 25.53 | 
| 1st DOWN Forecast | 12.71 | 
| 2nd DOWN Forecast | 8.21 | 
| 3rd DOWN Forecast | 3.71 | 
| 4th DOWN Forecast | -3.56 | 
                                        Zymeworks Inc ( NYSE USA Symbol : ZYME ) 
Sector : Healthcare And Other Stocks in Same Sector
                                    
                                    
                                Sector : Healthcare And Other Stocks in Same Sector
ZYME Other Details
                    | Segment | EQ | |
| Market Capital | 1054913664.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
ZYME Address
                                 |  | ||
                                        ZYME Latest News
                                    
                                    
                                    ZYME Business Profile
   
	 Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Address: 1385 West 8th Avenue, Vancouver, BC, Canada, V6H 3V9 
	
            
            © 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
 
	   Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

